🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Relmada shares plunge on Phase 3 trial failure

EditorFrank DeMatteo
Published 12/04/2024, 08:58 AM
© Reuters.
RLMD
-

CORAL GABLES, Fla. - Relmada Therapeutics , Inc. (NASDAQ:RLMD) experienced a significant drop in its stock value, falling 75% during pre-open trading on Wednesday. The decline came after the company disclosed that the independent Data Monitoring Committee (DMC) found the Phase 3 Reliance II study of REL-1017, intended as an adjunctive treatment for major depressive disorder (MDD), to be futile based on interim analysis. The DMC's assessment suggests that the trial is unlikely to achieve its primary efficacy endpoint with statistical significance.

Chief Executive Officer of Relmada, Sergio Traversa, expressed disappointment with the interim analysis outcome. Traversa stated, "Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program." He also acknowledged the contributions of the investigative sites and patients involved in the trial.

Despite the setback with REL-1017, Relmada confirmed its ongoing commitment to the development of REL-P11, a candidate for treating metabolic disease, which is currently in a Phase 1 first-in-human study. The company also reported a robust financial position, with approximately $54.1 million in cash and cash equivalents as of September 30, 2024.

It is important to note that while the DMC did not find any new safety concerns related to REL-1017, the futility of the Reliance II trial at this stage indicates a reassessment of the program's future is necessary. Relmada is expected to conduct a thorough review of the available data to inform its strategic decisions moving forward.

Commenting on the news, Mizuho (NYSE:MFG) analyst Uy Ear said, "We're hoping for the DMC to recommend no or a modest sample size increase from the interim analysis given the protocol changes & rigorous trial oversight. The futility finding is truly disappointing & likely means end for REL-1017 in MDD. RLMD likely to trade down sharply."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.